BCL2A1 and inflammatory bowel disease: Finally, it remains to be explored whether BCL2A1 and CEBPB can be incorporated into existing diagnostic protocols as potential biomarkers for both IBD and Sepsis, with the aim of improving disease detection and prognosis.